Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019

Breast Cancer Research(2024)10.1186/s13058-024-01822-9Source: DataRank Database

Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019 is a research paper published in Breast Cancer Research (2024). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 2.11)OA: goldTopics (59)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Kelli O’Connell ORCID,Isaac J. Ergas ORCID,Marilyn J. Foley,Grace Gallagher ORCID,Jennifer J. Griggs ORCID

Live enrichment

PubMed:38872192 PMC:PMC11170793 OpenAlex:https://openalex.org/W4399610450

NCI NIH HHS

Grant: R50CA2111115

National Cancer Institute

Grant: R37CA222793

NCI NIH HHS

Grant: R01 CA230440

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: R01 CA253028

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 5R37CA222793-04

Obesity, chemotherapy dosing, and breast cancer outcomes

Geoffrey Beene Cancer Research Center

FWCI

2.11

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1186/s13058-024-01822-9

publisherhttps://doi.org/10.1186/s13058-024-01822-9

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38872192

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11170793

repositoryhttps://doaj.org/article/e4df8f5cdae74a1a8836527359a19293

Fields of Study

Breast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchAdvanced Breast Cancer Therapies03 medical and health sciences0302 clinical medicineHumansFemaleBreast NeoplasmsMiddle AgedNeoplasm StagingAdultAgedAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesTrastuzumabChemotherapy, AdjuvantYoung Adult

MeSH Terms

TrastuzumabAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansMiddle AgedNeoplasm StagingChemotherapy, AdjuvantReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyYoung Adult

Keywords

MedicineBreast cancerChemotherapyTrastuzumabPertuzumabInternal medicineStage (stratigraphy)OncologySurgical oncologyCancerepidemiologyAntineoplasticsAdultBrief ReportNeoplasms. Tumors. Oncology. Including cancer and carcinogensBreast NeoplasmsMiddle AgedErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyYoung AdultChemotherapy, AdjuvantAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRC254-282Neoplasm StagingAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019

FAIR Checklist

Authors (22)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)